These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1193 related items for PubMed ID: 10751847

  • 21. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R, Winquist E, Lukka H, Chin JL, Brundage M, Markman BR, Cancer Care Ontario Practice Guidelines Initiative Genitourinary Cancer Disease Site Group.
    Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
    [Abstract] [Full Text] [Related]

  • 22. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
    Matsui Y, Nishiyama H, Watanabe J, Teramukai S, Ono Y, Ohshima S, Fujimoto K, Hirao Y, Fukushima M, Ogawa O.
    Int J Clin Oncol; 2005 Apr; 10(2):133-8. PubMed ID: 15864700
    [Abstract] [Full Text] [Related]

  • 23. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer.
    Qureshi KN, Griffiths TR, Robinson MC, Marsh C, Roberts JT, Hall RR, Lunec J, Neal DE.
    Clin Cancer Res; 1999 Nov; 5(11):3500-7. PubMed ID: 10589764
    [Abstract] [Full Text] [Related]

  • 24. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
    de Vries RR, Nieuwenhuijzen JA, Meinhardt W, Bais EM, Horenblas S.
    Eur J Surg Oncol; 2009 Apr; 35(4):352-5. PubMed ID: 18722076
    [Abstract] [Full Text] [Related]

  • 25. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N, Arima K, Sugimura Y.
    Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
    [Abstract] [Full Text] [Related]

  • 26. [Neoadjuvant chemotherapy (M-VAC) in invasive cancer of the bladder. Our experience].
    González Enguita C, Caro Cebrián C, Roncalés Badal A, Gil Sanz MJ, Martínez Bengoechea J, Rioja Sanz LA.
    Arch Esp Urol; 1990 Sep; 43 Suppl 2():197-204. PubMed ID: 2096779
    [Abstract] [Full Text] [Related]

  • 27. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C, Hall P, Pwint T, Al-Terkait F, Crew J, Powles T, Macaulay V, Munro N, Douglas D, Kilbey N, Protheroe A, Chester JD.
    Cancer; 2012 Aug 15; 118(16):3920-7. PubMed ID: 22614698
    [Abstract] [Full Text] [Related]

  • 28. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J, Crego M, Sabaté S, Salvador J, Palou J, Villavicencio H.
    Eur Urol; 2005 Jul 15; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [Abstract] [Full Text] [Related]

  • 29. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E, Iborra I, Rubio J, Casanova J, Almenar S.
    BJU Int; 2004 Dec 15; 94(9):1258-62. PubMed ID: 15610101
    [Abstract] [Full Text] [Related]

  • 30. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.
    Dotan ZA, Kavanagh K, Yossepowitch O, Kaag M, Olgac S, Donat M, Herr HW.
    J Urol; 2007 Dec 15; 178(6):2308-12; discussion 2313. PubMed ID: 17936804
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED.
    J Urol; 2007 May 15; 177(5):1727-31. PubMed ID: 17437798
    [Abstract] [Full Text] [Related]

  • 35. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
    Lehmann J, Retz M, Wiemers C, Beck J, Thüroff J, Weining C, Albers P, Frohneberg D, Becker T, Funke PJ, Walz P, Langbein S, Reiher F, Schiller M, Miller K, Roth S, Kälble T, Sternberg D, Wellek S, Stöckle M, AUO-AB 05/95.
    J Clin Oncol; 2005 Aug 01; 23(22):4963-74. PubMed ID: 15939920
    [Abstract] [Full Text] [Related]

  • 36. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K, Chihara Y, Kondo H, Hirao Y.
    Hinyokika Kiyo; 2006 Jun 01; 52(6):433-8. PubMed ID: 16848356
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Postoperative adjuvant M-VAC chemotherapy for invasive bladder cancer].
    Yamashita S, Taniguchi K, Morimitsu H, Suzu H, Kanetake H, Saito Y, Yushita Y, Sakuragi T.
    Hinyokika Kiyo; 1992 May 01; 38(5):519-24. PubMed ID: 1609658
    [Abstract] [Full Text] [Related]

  • 39. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
    Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP.
    J Urol; 2006 Dec 01; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
    [Abstract] [Full Text] [Related]

  • 40. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
    Wei CH, Hsieh RK, Chiou TJ, Chen KK, Chang LS, Chen PM.
    J Urol; 1996 Jan 01; 155(1):118-21. PubMed ID: 7490806
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 60.